ERBB2 and colorectal carcinoma: Current results demonstrate BDC-1001 to be well tolerated and clinically efficient also in patients previously treated with anti-HER2 therapy; however, the safety and efficacy of combining with a PD1 inhibitor is yet to be studied [6,41], although the data on PD-L1 expression in CRC with its regards to microsatellite instability remain controversial [38].